Mindfulness for Pain and Suicide
A Pilot Study on Mindfulness for Pain and Mental Health Outcomes
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Lisham Ashrafioun, PhD
- Phone Number: 585-430-2026
- Email: lisham.ashrafioun@va.gov
Study Locations
-
-
New York
-
Canandaigua, New York, United States, 14424
- Department of Veterans Affairs Center of Excellence for Suicide Prevention
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- English-speaking veterans
- Ages 18 years and older
- Understand informed consent
- Report pain that occurs on at least half the days for six months or more
- Score at least a 4 on each item of the three items on a brief pain intensity and interference measure
- To meet the minimum threshold for suicide risk, veterans must meet at least one of the following: (1) endorse at least a 1 ("several days") on item 9 ("thoughts of you would be better off dead, or thoughts of hurting yourself in some way" in the past 2 weeks) of the Patient Health Questionnaire-9 (PHQ-9), (2) endorse at least "death ideation" in the last 3 months as measured by the Columbia Suicide Severity Rating Scale, or (3) report a suicide attempt in the last 6 months.
Exclusion Criteria:
- An active severe substance use disorder (SUD)
- Documented schizophrenia, active psychosis, or mania
- Upcoming surgeries
- Uncontrolled medical conditions
- Intent to carry out a plan for suicide.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Mindfulness-Based Cognitive Therapy (MBCT)
MBCT delivered over the course of 10, ~60 minute sessions
|
10 sessions focused on increasing mindfulness awareness to address thoughts, emotions, and behaviors that maintain functional impairment and risk of suicide.
|
|
Active Comparator: Health Education
Health education sessions delivered over the course of 10, ~60 minute sessions
|
Health education provides information on the importance and benefits of and guidelines for living a healthy lifestyle.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Treatment Acceptability
Time Frame: 1-month post-treatment
|
The Abbreviated Acceptability Rating Profile assesses the extent to which participants agree with 8 statements about the intervention.
Scores range from 1 to 6 with higher scores indicating higher acceptability.
Data are from the 1-month follow-up assessment.
|
1-month post-treatment
|
|
Suicidal Ideation Intensity
Time Frame: 6-month post treatment follow-up
|
Suicide ideation intensity will be assessed using the Columbia Suicide Severity Rating Scale Ideation intensity subscale.
Scores range from 2 to 25 with higher scores indicating greater intensity of ideation.
Data are from the 6-month follow-up assessment.
|
6-month post treatment follow-up
|
|
Depression
Time Frame: 6 months post-treatment follow-up
|
The Patient Health Questionnaire-9 was used to assess depression symptoms.
Scores range from 0 to 27 with higher scores indicating greater severity of depression.
Data are from the 6-month follow-up assessment.
|
6 months post-treatment follow-up
|
|
Interpersonal Needs
Time Frame: 6-months post-treatment follow-up
|
The Interpersonal Needs Questionnaire was used to assessed interpersonal needs.
Scores range from 12 to 84 with higher scores indicating greater conflict with interpersonal needs.
Data are from the 6-month follow-up assessment.
|
6-months post-treatment follow-up
|
|
Pain Interference
Time Frame: baseline to 6 months post-treatment follow-up
|
Pain interference was measured using the Brief Pain Inventory.
Scores range from 0 to 10 with higher scores indicating greater pain-related interference in activities.
Data are from the 6-month follow-up assessment.
|
baseline to 6 months post-treatment follow-up
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Physical Health-related Quality of Life
Time Frame: 6 months post-treatment follow-up
|
The Veterans Rand (VR)-12 was used to assess physical health-related quality of life.
Scores fall between 20 and 60 in clinical populations with higher scores indicating higher physical health-related quality of life.
Data are from the 6-month follow-up assessment.
|
6 months post-treatment follow-up
|
|
Pain Intensity
Time Frame: baseline to 6 months post-treatment follow-up
|
Pain intensity was assessed using the Brief Pain Inventory Pain Severity subscale.
Scores range from 0 to 10 with higher scores indicating more severe pain intensity.
Data are from the 6-month follow-up assessment.
|
baseline to 6 months post-treatment follow-up
|
|
Mental Health-related Quality of Life
Time Frame: 6-months post treatment assessment
|
The Veterans Rand (VR)-12 was used to assess mental health-related quality of life.
Scores fall between 20 and 60 in clinical populations with higher scores indicating higher mental health-related quality of life.
Data are from the 6-month follow-up assessment.
|
6-months post treatment assessment
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mindfulness
Time Frame: 6 months post-treatment follow-up
|
We used the Five Facet Mindfulness Questionnaire (FFMQ) to assess mindfulness.
Scores range from 39 to 195 with higher scores indicating higher mindfulness.
Data are from the 6-month follow-up assessment.
|
6 months post-treatment follow-up
|
|
Pain Acceptance
Time Frame: 6 months post-treatment follow-up
|
Pain acceptance was assessed using the Chronic Pain Acceptance Questionnaire (CPAQ) scores range from 0 to 120 with higher scores indicating greater acceptance of pain with higher scores indicating greater pain acceptance.
|
6 months post-treatment follow-up
|
|
Pain Catastrophizing
Time Frame: baseline to 6 months post-treatment follow-up
|
Pain catastrophizing was assessed using the Pain Catastrophizing Scale (PCS).
Scores range from 0 to 52 with higher scores indicate greater pain catastrophizing.
Data are from the 6-month follow-up assessment.
|
baseline to 6 months post-treatment follow-up
|
|
Fear of Movement
Time Frame: baseline to 6 months post-treatment follow-up
|
Fear of movement due to pain will be measured using the Tampa Scale of Kinesiophobia.
The scores range from 17-68 with higher scores indicating indicating greater fear of movement.
Data are from the 6-month follow-up assessment.
|
baseline to 6 months post-treatment follow-up
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Behavioral Symptoms
- Self-Injurious Behavior
- Suicide
- Pathological Conditions, Signs and Symptoms
- Behavior
- Signs and Symptoms
- Suicidal Ideation
- Chronic Pain
- Suicide, Attempted
- Behavior Therapy
- Psychotherapy
- Behavioral Disciplines and Activities
- Cognitive Behavioral Therapy
- Mindfulness
- Mindfulness-Based Cognitive Therapy
Other Study ID Numbers
Other Study ID Numbers
- 1600604
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.